Stock Valuation / LLY
Is Eli Lilly and Company (LLY) Overvalued? Fair Value & 5-Year Target
Eli Lilly and Company trades at $1,166.51 (P/E 39.14). Our reference model estimates a fair value of $793.50 at its recent average P/E of 26.63.
| Current price | $1,166.51 |
|---|---|
| Current EPS | $29.80 |
| Current P/E | 39.14 |
| Average P/E | 26.63 |
| Fair value (at avg P/E) | $793.50 |
| Upside to fair value | -32.0% |
| Illustrative 5-yr target (25× P/E, 15% growth) | $1,498.46 |
What drives LLY's valuation
Changing either assumption moves the target: a higher P/E multiple or faster EPS growth raises fair value, a lower multiple or slower growth lowers it. The interactive dashboard lets you edit both and re-run the model instantly.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for color
Frequently asked questions
What is LLY's fair value?
At its recent average P/E of 26.63, Eli Lilly and Company (LLY) has a reference fair value of about $793.50, which is -32.0% versus the current price of $1,166.51.
Is Eli Lilly and Company (LLY) overvalued or undervalued?
Based on the average-P/E reference model, Eli Lilly and Company looks overvalued relative to fair value by roughly +32.0%. This is a model output, not investment advice — change the P/E and growth assumptions in the dashboard for your own view.
What is a 5-year price target for LLY?
Under an illustrative model of 25× P/E and 15% annual EPS growth, the implied 5-year target is $1,498.46. Adjust both inputs on the interactive page to match your assumptions.
Open the interactive LLY valuation dashboard →
Figures are for informational purposes only and are not investment advice. Data as of 2026-10-14.